Spyre Therapeutics, Inc. (SYRE)
After hours:
| Previous close | 32.36 |
| Open | 31.78 |
| Bid | 31.36 x 100 |
| Ask | 31.66 x 100 |
| Day's range | 30.84 - 32.60 |
| 52-week range | 2.65 - 47.97 |
| Volume | |
| Avg. volume | 370,577 |
| Market cap | 1.6B |
| Beta (5Y monthly) | 2.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 09 Aug 2024 - 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 45.00 |
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 83,000 shares of common stock of Spyre to 3 non-executive emplo
- PR Newswire
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in a fireside chat and investor meetings at the Jefferies Global Healthcare Conference. Details of the fireside are as follows:
- PR Newswire
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced the appointment of Sandra Milligan, M.D., J.D., President of Aspira Women's Health, to its Board of Directors.
